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Urinary aquaporin-2 in healthy humans and patients with liver The vasopressin (AVP)-sensitive water channel aqua-
cirrhosis and chronic heart failure during baseline conditions porin-2 (AQP-2) mediates water transport across the
and after acute water load. apical plasma membrane of the renal collecting ducts [1].Background. Patients with liver cirrhosis and chronic heart
The permeability of the collecting ducts is dependent onfailure (CHF) have a reduced capacity to excrete water. Studies
the water channels located at the apical membrane. AVPin healthy humans have shown that an acute water load reduces
the excretion of aquaporin-2 in urine (u-AQP-2). We wanted to acts on a short-term basis through the cyclic adenosine
test the hypothesis that an acute water load reduces u-AQP-2 monophosphate (cAMP)/protein kinase A (PKA) signal-
less in patients with liver cirrhosis or CHF than in healthy ing pathway translocating AQP-2 from intracellular vesi-humans.
cles to the apical plasma membrane of the collecting ducts.Methods. Fourteen healthy subjects, 14 patients with liver
When AVP levels decline, AQP-2 is retrieved by endocy-cirrhosis, and 14 patients with CHF were given an oral water
load of 20 mL/kg. Urine was collected every 30 minutes for 4 tosis, and the membrane returns to its resting state of
hours for analysis of u-AQP-2. Blood samples were drawn at lower water permeability [2–4]. AVP also regulates the
the beginning and at the end of the study for analysis of arginine
long-term water permeability of the collecting ducts byvasopressin (AVP). u-AQP-2 was determined by radioimmu-
increasing AQP-2 gene expression. The increase in tran-noassay.
Results. During the study period, urinary output was 22.8% scription may be the result of the ability of cAMP to
higher than water intake in the healthy controls and increased activate PKA, resulting in phosphorylation of transcrip-
14-fold from baseline, but in patients with liver cirrhosis and tion factors such as cAMP regulatory element binding
CHF urinary output was 14% and 24% less than the intake,
protein (CREB) [5–7]. The long-term regulation increaseswhile urinary output increased 7- and 19-fold from baseline,
the total amount of AQP-2 available for the modulationrespectively. u-AQP2 decreased significantly more in patients
with CHF (39%) than in healthy controls (17%) but it was of the apical membrane’s water permeability.
unchanged in those with liver cirrhosis. AVP decreased 46% AQP-2 is excreted into the urine [8–9] and can be
in patients with CHF, but was unchanged in healthy controls quantified by either radioimmunoassay [10] or quantita-and those with liver cirrhosis. A 24-hour urinary excretion of
tive Western blot analysis [11]. Short-term studies haveAQP-2 was significantly elevated in patients with CHF (me-
shown that urinary AQP-2 excretion (u-AQP-2) can bedian, 25.7 nmol/mol creatinine) compared to healthy controls
(15.7 nmol/mol creatinine) and those with liver cirrhosis (17 used as a marker for the action of AVP on the collecting
nmol/mol creatinine). ducts [10].
Conclusion. The excretion of AQP-2 in urine is abnormal Chronic heart failure (CHF) is generally associatedboth in liver cirrhosis in which we find less suppression of
with marked defects in the renal handling of sodium andu-AQP2 by an acute water load and in CHF in which we
find a high baseline level and an exaggerated suppression of water resulting in extracellular fluid expansion and in
u-AQP2 by an acute water load. severe CHF with hyponatremia. Studies have shown that
AVP is increased in rats with congestive heart failure
and that there is an increased expression of AQP-2
mRNA [12]. Furthermore, the total amount of AQP-2
is increased, especially at the localization of the apicalKey words: urinary aquaporin-2, water load, healthy humans, water
retention. membrane [13]. Studies in rats with liver cirrhosis with
and without ascites have shown different results regard-Received for publication November 5, 2001
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and did not change after an acute water load. However, impairment in renal function defined as a creatinine
clearance  40 mL/min.other studies have shown a decrease in AQP-2 expres-
For the CHF patients, the following inclusion criteriasion in rats with compensated liver cirrhosis [15] and in
were used: (1) men and women, (2) age, 35 to 75 yearsdecompensated liver cirrhosis [16].
old; (3) New York Heart Association (NYHA) class IIThe exact role of AQP-2 under conditions of sodium
or III; and (4) left ventricular (LV) systolic dysfunctionand water retention is not fully clarified in humans. The
as evidenced by an LV ejection fraction  40% docu-effect of an acute oral water load on u-AQP-2 and its
mented by echocardiography within 6 months of studyrelationship to AVP and urinary osmolality (u-osm) in
enrollment. Exclusion criteria were (1) a history or clini-healthy humans, in patients with liver cirrhosis, and in
cal signs of disease of the lungs, liver, or endocrine or-patients with CHF has not been studied by simultaneous
gans; (2) neoplastic disease; (3) arterial hypertension;measurement of other important regulatory hormons of
(4) alcohol abuse; (5) treatment with cyclooxygenasethe water and sodium homeostasis such as the renin-
inhibitors; (6) unwillingness to participate; and (7) sig-angiotensin-aldosterone system and the natriuretic pep-
nificant impairment in renal function defined as a creati-tides
nine clearance  40 mL/min.The purpose of the present study was to measure the
The studies was approved by the local medical ethicseffect of an acute water load on (1) urinary excretion
committee, and written informed consent was obtainedof AQP-2, (2) plasma concentration of vasopressin, (3)
from all participants.urine osmolality, (4) the renin-angiotensin-aldosterone
system, and (5) the natriuretic peptide system. We Experimental procedures
wished to test the hypotheses that urinary excretion of
A 24-hour urine collection was performed the dayAQP-2 was reduced less in patients with liver cirrhosis
before the study. All medication was withdrawn 24 hoursand CHF than in healthy controls after an acute oral
before the study. The subjects were allowed to drinkwater load, and that baseline levels of u-AQP-2 were
freely until the beginning of the study. Smoking washigher in liver cirrhosis and CHF than in controls.
prohibited during the study. Baseline was the period
from the end of the 24-hour urine collection to just before
METHODS the water load. An indwelling catheter for blood sam-
pling was placed in a forearm vein. After voiding, a waterSubjects
load of 20 mL/kg was given orally for 15 minutes. Urine
For the healthy subjects, the following inclusion crite-
was collected every 30 minutes for 4 hours. Voiding took
ria were used: (1) men and women; and (2) age, 35 to place in the standing or sitting position. Blood samples
75 years old. Exclusion criteria were (1) a history or were drawn at the beginning and at the end of the study.
clinical signs of disease of the heart, lungs, liver, kidneys Plasma was analyzed for AVP, osmolality (osm), renin
or endocrine organs; (2) neoplastic disease; (3) arterial concentration (PRC), angiotensin II (Ang II), aldoste-
hypertension; (4) alcohol or drug abuse; (5) medical rone, atrial natriuretic peptide (ANP), brain natriuretic
treatment except for birth control pills; (6) unwillingness peptide (BNP), sodium, and hemotocrit. Urine was ana-
to participate; and (7) abnormal laboratory screening lyzed for AQP-2 concentration, urine osmolality (u-osm),
tests (i.e., abnormal blood hemoglobin, white cell count, urine creatinine concentration (u-creatinine), and urine
platelets, p-sodium, p-potassium, p-creatinine, p-albu- sodium concentration.
min, b-glucose, s-cholesterol, p-bilirubin and p-alanine
aminotransferase, or albuminuria or glucosuria). Measurements
For the liver cirrhosis patients the following inclusion AQP-2 was measured by radioimmunoassay, as pre-
criteria were used: (1) men and women; (2) age, 35 to viously described [10]. Urine samples was centrifuged
75 years old; and (3) cirrhosis based on liver histology for 5 minutes at 1.6  100g (3000 rpm) and 125 to 3000
or in the absence of a liver biopsy, anamnestic, clinical, L of the supernatant (depending on u-osm) was freeze-
and laboratory evidence of cirrhosis, including ascites, dried and kept frozen at 20C until assayed. For radio-
esophagogal varices (verified by endoscopy), hypoal- immunoassay rabbit anti-AQP-2 antibody was obtained
buminemia, and increased p-alanine aminotransferase. from Søren Nielsen (Department of Cell Biology, Insti-
Exclusion criteria were (1) a history or clinical signs tute of Anatomy, Aarhus University, Aarhus, Den-
of disease of the lungs, heart or endocrine organs; (2) mark). The minimum detection level was 32 pg/tube.
neoplastic disease; (3) arterial hypertension; (4) treat- The coefficients of variation were 11.7% (interassay) and
ment with cyclooxygenase inhibitors; (5) positive hepi- 5.9% (intra-assay).
titis B surface antigen (HbsAg), positive hepatitis B en- AVP in plasma was measured by radioimmunoassay,
dothelial antigen (HbeAg), or positive antihepititis C which was a modification of the method described pre-
viously [17]. Before the assay procedure C18 Sep-Pakvirus; (6) unwillingness to participate; and (7) significant
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(Water Associates, Milford, MA, USA) extraction was Statistics
performed. The antibody was a gift from professor Data from 14 healthy subjects, 14 patients with liver
Jacques Du¨rr (Miami, Florida, USA). The minimum de- cirrhosis, and 14 patients with CHF were included in the
tection level was 0.5 pmol/L. The coefficients of variation statistical analyzes. Due to lack of normality or inhomo-
were 13% (interassay) and 9% (intra-assay). geneity of the variance we used Friedman’s ANOVA
PRC was measured by a commercial immunoradiome- (analysis of variance) for paired comparisons within the
tric assay (Nichols Institute Diagnostics, Geneva, Swit- groups followed by comparisons between baseline and
zerland). The coefficients of variation were 2.5% (intra- the other periods as described by Siegel and Castellan
assay) and 9.9% (interassay). Minimal detection level [22]. Since baseline values were different between healthy
was 1.4 U/mL. subjects and patients, we compared relative changes
Ang II in plasma was determined by radioimmunoas- from baseline by comparing healthy subjects on one hand
say using a modification [18] of the method originally and patients on the other. Between groups comparisons
described by Kappelgaard, Damkjaer-Nielsen, and Giese were performed with Kruskal-Wallis’s test for unpaired
[19]. Radioimmunoassay was performed after previous comparisons followed by Mann-Whitney’s rank sum test.
extraction of plasma by C18 Sep-Pak cartridges (Water P  0.05 was considered the limit of significance.
Associates). The antibody was obtained from the De-
partment of Clinical Physiology, Glostrup Hospital RESULTS
(Glostrup, Denmark). Minimal detection level was 2
Demographicspmol/L plasma. The coefficients of variation were 12%
Fourteen healthy subjects of mean age of 60 years(interassay) and 8% (intra-assay).
(range, 44 to 64 years old), six men and eight women,Aldosterone in plasma was measured by a modifica-
were studied.tion [18] of the method originally described [20]. With
Fourteen patients with liver cirrhosis of mean age 54a rabbit anti-Aldo antibody (Simoco, Denmark) radio-
years (range, 42 to 62 years old), eight men and siximmunoassay was performed after extraction of plasma
women participated in the study. Nine patients had cir-by C18 Sep-Pak cartridges (Water Associates). The mini-
rhosis verified by a liver biopsy. The five patients inmum detection level was 42 pmol/L plasma. The coeffi-
which a liver biopsy had not been performed had yearscients of variation were 13% (interassay) and 9% (intra-
of excessive alcohol abuse. All had ascites, and one hadassay).
portal hypertension. Five patients had esophageal vari-ANP in plasma was determined by radioimmunoassay,
ces (three ascites patients) and two patients had portalas previously described [18]. ANP was extracted from
hypertension (one ascites patient) verified by ultrasound.plasma by means of C18 Sep-Pak cartridges (Water Asso-
Nine patients (six patients with ascites) received diureticciates), using ethanol, acetic acid, and water. For radio-
treatment. The diuretic treatment consisted of eitherimmunoassay rabbit anti-ANP antibody was obtained
spironolactone (six patients) or a combination therapyfrom the Department of Clinical Chemistry, Bispebjerg
of spironolactone and furosemide (three patients). TheHospital (Copenhagen, Denmark). The minimum detec-
cirrhotic patients treated with diuretics were in a statetion level was 0.5 pmol/l plasma. The coefficients of varia-
of normohydration or with mild-to-moderate leg edemation were 12% (interassay) and 10% (intra-assay).
and ascites.BNP in plasma was measured by radioimmunoassay,
Fourteen patients with CHF of mean age 65 years
previously described [21]. Immunoreactive BNP was ex- (range, 49 to 74 years old), 11 men and three women
tracted from plasma by use of C18 Sep-Pak cartridges were studied. The etiology of CHF was ischemic heart
(Water Associates) eluted by 80% ethanol in a 4% acetic disease (93%) and cardiomyopathy (7%). Nine patients
acid solution. Radioimmunoassay was performed using were in NYHA class II [left ventricular ejection fraction
a rabbit anti-BNP antibody without cross-reactivity with (LVEF), mean 28%] and five in NYHA class III (LVEF,
-ANP and urodilatin (URO). The minimum detection mean 29%). Medication included digoxin, diuretics, an-
level was 0.5 pmol/L plasma. The coefficients of variation giotensin-converting enzyme (ACE) inhibitors, Ang II
were 11% (interassay) and 6% (intra-assay). inhibitors, aspirin, warfarin, isosorbide mononitrate,
Plasma and urinary concentrations of sodium and po- statins, beta blockers, and amiodarone. Four patients
tassium were measured by routine methods at the De- had an ICD pacemaker. All patients were in a clinically
partment of Clinical chemistry, Holstebro Centralsy- stable condition. Clinical and laboratory data for all par-
gehus. Plasma and urinary osmolality was measured by ticipants are given in Table 1.
freezing-point depression (Advanced model 3900 multi-
Water balance during the studysample osmometer).
Blood pressure was determined by UA-743 digital The water intake was 1605 mL (25th percentile, 1362;
75th percentile, 1669) in healthy subjects, 1562 mL (1253blood pressure meter (A&D Cmpany, Ltd., Japan).
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Table 1. Clinical and laboratory data for 14 healthy subjects, 14 patients with liver cirrhosis, and 14 patients with chronic heart failure
(CHF). Urine analyses are based on 24-hour urine collections the day before the studies
Healthy Cirrhosis CHF
Number 14 14 14
Men/women 6/8 8/6 11/3
Years 60 (44–64) 54 (42–62) 65 (49–74)
Body mass index 26.6 (24.3–28.4) 29.2 (23.6–32)a 24.7 (22.4–29.3)a
Systolic blood pressure mm Hg 120 (114–136) 110 (98–116)a 115 (103–129)a
Diastolic blood pressure mm Hg 75 (72–80) 67 (60–72)a 64 (60–74)a
Pulse rate min 65 (62–68) 67 (62–81)a 60 (55–66)a
p-sodium mmol/L 141 (139–142) 136 (135–139)b 138 (136–139)b
p-potassium mmol/L 3.8 (3.7–3.9) 3.9 (3.6–4.3)a 3.9 (3.9–4.3)a
p-creatinine lmol/L 87 (82–100) 78 (69–93)a 100 (83–143)a
s-osmolality mosmol/kg 290 (288–292) 287 (280–291)a 287 (284–292)a
u-sodium excretion mmol/day 195 (160–227) 156 (84–226)a 199 (130–262)a
Median with 25% and 75% percentiles.
aNot significant compared to healthy subjects
bP  0.05 compared to healthy subjects
to 1839) in patients with liver cirrhosis and 1469 mL Plasma AVP
(1257 to 1826) in patients with CHF. During the study, The absolute values of AVP in healthy subjects, in
the total urinary output was 1973 mL (1647 to 2024) in patients with liver cirrhosis, and patients with CHF are
healthy subjects, 1343 mL (729 to 1744) in patients with shown in Figure 3. AVP was unchanged during the study
liver cirrhosis and 1111 mL (601 to1390) in patients with in healthy subjects and in patients with liver cirrhosis.
CHF. When the total amount of urinary output was AVP was significantly higher in patients with liver cirrho-
compared with the amount of water intake the urinary sis compared to healthy subjects at baseline (48%, P 
output was 22.8% larger than the water intake in healthy 0.05), but no significant difference in relative values was
subjects, but 14% less in patients with liver cirrhosis and observed between healthy subjects and patients with
24% less in patients with CHF. liver cirrhosis during the experiment. AVP decreased by
46% during the study in patients with CHF (P  0.005).
u-AQP-2 AVP was significantly elevated at baseline in CHF pa-
Figure 1 shows u-AQP-2 given as nanomole per mole tients (155%, P  0.006) compared to healthy subjects,
creatinine in healthy subjects, in patients with liver cirrho- and the changes in relative values were significantly
sis, and patients with CHF. In healthy subjects, u-AQP-2 greater in CHF patients (43%, P  0.004) compared to
was almost unchanged during the study except after 210 healthy subjects (13%).
minutes where a 17% (P  0.05) decrease was found.
Osm in urine and urinary outputIn patients with liver cirrhosis, u-AQP-2 was unchanged
during the study and no differences were observed in Figure 4 shows u-osm in healthy subjects, in patients
the relative changes in u-AQP-2 between patients with with liver cirrhosis, and patients with CHF. In healthy
liver cirrhosis and healthy subjects, at baseline or during subjects, u-osm decreased significantly with a maximum
the study (Fig. 2). u-AQP-2 decreased throughout the decrease of 88% after 120 minutes. At the end of the
study in patients with CHF and was significantly lower study, u-osm did not deviate significantly from baseline in
after 120 minutes with a maximal 39% decrease after healthy subjects. In patients with cirrhosis u-osm decreased
210 minutes. u-AQP-2 was significantly greater in CHF significantly after 90 minutes. The maximal decrease was
patients compared to healthy subjects at baseline (54%, seen after 120 minutes and was 72%. Subsequently, u-osm
P  0.03) and the relative decreases in u-AQP-2 was slowly increased but was still significantly lower than base-
significantly stronger in patients with CHF compared to line at the end of the study. There was no significant
healthy subjects from 120 minutes (P  0.007) and until difference between healthy subjects and patients with liver
the end of the study (Fig. 2). cirrhosis at baseline. The relative decrease in u-osm was
In healthy subjects, patients with liver cirrhosis, and significantly less in patients with liver cirrhosis compared
CHF patients the 24-hour u-AQP2 excretion was 15.7 to healthy subjects between 30 and 180 minutes. In CHF
nmol/mol creatinine (25th percentile, 13.8; 75th percentile, patients, u-osm decreased significantly after 90 minutes.
19.2), 17 nmol/mol creatinine (13.6 to 19.7), and 25.7 nmol/ The maximal decrease was seen after 150 minutes and was
mol creatinine (18.7 to 36.3), respectively. The 24-hour 80%. Subsequently there was a slow increase, but u-osm
u-AQP-2 excretion was significantly increased in patients was still significantly lower than baseline at the end of
the study. There was no significant difference betweenwith CHF compared to healthy subjects (P  0.003).
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increases were significantly greater in CHF patients com-
pared to healthy subjects (data not shown).
PRC, Ang II, aldosterone, ANP, and BNP
Table 2 shows PRC, Ang II, aldosterone, ANP, and
BNP in healthy subjects, patients with liver cirrhosis,
and patients with CHF. PRC and aldosterone were sig-
nificantly decreased during the study in healthy subjects
and in CHF patients with only a tendency toward a
decrease in patients with liver cirrhosis. The decrease in
PRC was significantly greater in CHF patients compared
to healthy subjects. Ang II and ANP were unchanged
in all the groups. BNP increased significantly in patients
with CHF with no change in patients with liver cirrhosis
and healthy subjects. All the hormones were significantly
increased at baseline in CHF patients and in patients
with liver cirrhosis compared to healthy subjects.
Blood pressure and heart rate
Mean arterial blood pressure (MAP) and heart rate
were measured every 30 minutes. There was no signifi-
cant change in MAP in healthy subjects during the study.
MAP was significantly increased in patients with cirrho-
sis at 30 minutes and at 120 minutes [baseline, 80 mm Hg
(73 to 87); 30 minutes, 90 mm Hg (86 to 98, P  0.05);
120 minutes, 114 mm Hg (104 to 133, P  0.001)]. The
same pattern was seen in CHF patients [baseline, 82
mm Hg (73 to 91); 30 minutes, 94 mm Hg (87 to 103,
P  0.05); 120 minutes, 120 mm Hg (110 to 142, P 
0.001)]. Subsequently MAP decreased to baseline level
during the rest of the study in all patients. The heart
rate showed no change during the study in either of the
groups (data not shown).
DISCUSSION
In the present study of healthy subjects and patients
with liver cirrhosis and CHF, we investigated the effectFig. 1. Urinary excretion of aquaporin-2 (u-AQP2) after an acute wa-
ter load in 14 healthy subjects (A ), 14 patients with liver cirrhosis (B ), of an acute oral water load on u-AQP-2, water excretion,
and 14 patients with chronic heart failure (CHF) (C ). Baselines are and hormones in plasma of importance for renal function
from the end of the 24-hour urine collection to the beginning of the
and sodium and water homeostasis in 30-minute periodsstudy. Results are means with  SD. *P  0.05 vs. baseline; †P  0.05
vs. healthy subjects at baseline. from 8:00 a.m. to 12:00 a.m.
In healthy subjects, the total urinary output was greater
than the total water intake after an acute water load.
The acute water load resulted in a small but significanthealthy subjects and patients with CHF at baseline. The
decrease in u-AQP-2 but no change in AVP. In addition,relative decrease was also significantly smaller in patients
there was a substantial increase in urinary output and awith CHF compared to healthy subjects after 30 minutes
decrease in u-osm. Patients with liver cirrhosis had aand until 180 minutes.
reduced ability to excrete an acute water load. In addi-The maximal increase in urinary output was seen after
tion, they showed only a tendency toward a decrease in120 minutes and was 14-fold higher than at baseline
u-AQP-2 and AVP. The relative increases in urinaryin healthy subjects, 7.6-fold higher than at baseline in
output, and the relative decrease in u-osm was less thanpatients with liver cirrhosis and 19-fold higher than at
in healthy subjects. Patients with CHF also had a dimin-baseline in patients with CHF. The relative increases
ished capacity to excrete an acute water load with a 24%were significantly lower in patients with liver cirrhosis
compared to healthy subjects. In addition, the relative less urinary output than water intake. In patients with
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Fig. 2. Relative changes in urinary aquaporin-2
(u-AQP2) after an acute water load in 14 healthy
subjects (), 14 patients with liver cirrhosis
( ), and 14 patients with chronic heart failure
(). Baselines are from the end of the 24-hour
urine collection to the beginning of the study.
Results are means SD. †P 0.05 vs. healthy
subjects.
CHF, u-AQP2 and AVP decreased throughout the
study. The decrease in u-AQP2 was larger in patients
with CHF than in healthy subjects. The relative increases
in urinary output were larger in patients with CHF than
in healthy subjects, whereas the decrease in u-osm was
smaller. For ethical reason, we did not find it justified
to discontinue the medical treatment of the patients for
more than 24 hours. It is, therefore, possible that the
drugs still have a small effect on water balance.
The role of AQP-2 in cirrhosis has been studied exten-
sively in rats. The results have been conflicting with re-
gard to the renal expression of AQP-2. The initial studies
showed an increased level of AQP-2 protein and AQP-2
mRNA in carbon tetrachloride (CCL4)–induced cirrhotic
rats with ascites [14, 23]. In addition, an acute water load
did not decrease AQP-2 mRNA within 1 hour [14]. Liver
cirrhosis induced by common bile duct ligation (CBL)
showed a decreased expression of AQP-2 both in rats
with and without ascites [15, 16]. Recently, Jonassen et al
[24] showed no difference in the expression of AQP-2
protein in rats with CCL4-induced liver cirrhosis and
control rats. The rats had hyponatremia, ascites, andFig. 3. Plasma levels of vasopressin (AVP) at baseline and at 240
increased plasma level of AVP and showed an impairedminutes after an acute water load in 14 healthy subjects (), 14 patients
with liver cirrhosis ( ), and 14 patients with chronic heart failure (CHF) ability to excrete an intravenous water load. We are the
(). Baselines are from the end of the 24-hour urine collection to the first to study the role of AQP-2 in humans with liverbeginning of the study. Results are means SD. *P 0.05 vs. baseline;
†P 0.05 vs. healthy subjects; ††P 0.05 vs. healthy subjects at baseline. cirrhosis, and our results seem to be in agreement with
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Table 2. Plasma levels of renin (PRC), angiotensin II (Ang II),
aldosterone, atrial natriuretic peptide (ANP), and brain natriuretic
peptide (BNP) at baseline and 240 minutes after an acute water load
in 14 healthy subjects, 14 patients with liver cirrhosis, and 14
patients with chronic heart failure (CHF)
Baseline 240 min
PRC lU/mL
Healthy 14 (12–22) 12 (9–15)a
Liver cirrhosis 29 (13–54)b 23 (11–40)
CHF 73 (46–142)b 41 (22–86)a,c
Ang II pmol/L
Healthy 8.6 (4.5–11.7) 8.1 (5.5–13.6)
Liver cirrhosis 9.1 (3.8–14.8) 7.2 (4.8–14.8)
CHF 13.4 (7.4–18.7)b 10.2 (9.6–18.2)
Aldo pmol/L
Healthy 61.2 (45.9–105.0) 41.7 (35.4–50.0)a
Liver cirrhosis 122.3 (74.4–182.1)b 70.9 (40.3–207.1)
CHF 94.5 (61.1–149.4)b 50.0 (41.7–100.8)a
ANP pmol/L
Healthy 6.1 (5.5–6.9) 5.4 (4.4–7.0)
Liver cirrhosis 8.0 (3.9–10.5) 7.3 (4.4–9.8)
CHF 20.2 (13.3–41.1)b 21.0 (11.5–30.8)
BNP pmol/L
Healthy 1.9 (1.1–3.3) 2.0 (1.2–3.9)
Liver cirrhosis 4.2 (2.9–9.7)b 4.9 (3.0–11.9)
CHF 16.9 (9.1–44.8)b 18.7 (10.2–59.8)a
Median with 25% and 75% percentiles.
a P  0.05 vs. baseline; bP  0.05 vs. healthy subjects at baseline; cP  0.05
vs. healthy subjects
It has been demonstrated that AQP-2 protein and
mRNA expression is higher in rats with severe CHF
[12, 13], but, in the study by Nielsen et al [13], rats
with compensated CHF showed no increase in AQP-2
expression. In our study, the patients had hyponatremia,
increased basal AVP concentration, and a 24-hour urine
sample showed an increased excretion of AQP-2. De-
spite a larger increase in urinary output and a decrease
in u-AQP-2, the ability to dilute urine was impaired in
patients with CHF. They did not excrete all the ingested
water and the decrease in u-osm was less than in healthy
subjects. Thus, we have demonstrated that u-AQP-2 is
increased in patients with CHF, and that an acute water
load can suppress AVP and decrease u-AQP-2, but water
Fig. 4. Urinary osmolality (u-osm) after an acute water load in 14
excretion was not normalized.healthy subjects (A ), 14 patients with liver cirrhosis (B ), and 14 patients
with chronic heart failure (CHF) (C ). Baselines are from the end of The results of the present study show that AQP-2 was
the 24-hour urine collection to the beginning of the study. Results not up-regulated in patients with liver cirrhosis, despiteare medians with 25th, 75th, 10th and 90th percentiles. *P  0.05 vs.
an increase in AVP and an inability to excrete an acutebaseline.
water load normally. However, the increase in AVP was
only moderate and only six patients had ascites. This
might at least partly explain the absence of an increasethe findings in animal experiments by Jonassen et al [24].
in u-AQP-2 excretion. Possibly u-AQP-2 is increased inOur patients had hyponatremia, slightly but significantly
more advanced liver cirrhosis. The inability to excreteincreased AVP, and six patients had ascites or edema.
an acute water load by the cirrotic patients in our studyThe patients had impaired ability to excrete an acute
must, therefore, be due to a different mechanism, whichoral water load because the increase in urinary output
is unknown at present. One question to be answered iswas less than in healthy subjects, and the cirrhotic pa-
why the increase in AVP does not increase u-AQP-2tients did not excrete all the water they were given.
excretion. Ecelbarger et al [25] raised the question ofFurthermore, we only saw a tendency toward a decrease
in u-AQP-2. the existence of AVP-independent mechanisms for the
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regulation of AQP-2 expression and showed that, despite did not change ANP and BNP, while BNP increased in
patients with CHF. This difference may be attributed toa continuous subcutaneous infusion of 1-desamino-8-D-
AVP (synthetic AVP V2-receptor agonist), AQP-2 was differences in cardiac output, which is reduced in CHF
but often normal in liver cirrhosis.down-regulated after water loading. In addition, thirsting
of rats in the presence of chronic V2-receptor blockade
(OPC-31260) increases AQP-2 expression levels [26].
CONCLUSION
Thus, vasopressin-independent mechanisms might play
We have demonstrated that 24-hour urinary AQP-2a significant role in the abnormal water balance in liver
excretion was increased in patients with CHF but not incirrhosis.
cirrhotic patients compared to healthy subjects. An acuteEarlier studies have shown that AVP decreases in
water load did not change u-AQP-2 in patients withresponse to an acute water load in CHF patients [27, 28].
cirrhosis but decreased u-AQP-2 in patients with CHFThe decrease was maximal at 2 hours and AVP was
and even more than in healthy subjects. Our results indi-still significantly lower at 5 hours. AVP was significantly
cate that excretion of AQP-2 in urine is abnormal bothhigher in patients with CHF compared to healthy sub-
in liver cirrhosis and in CHF.jects throughout the study except after 5 hours. In our
study, we measured AVP after 4 hours, and there was
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